Last Updated: November 16, 2026

Details for Patent: 11,058,668

« Back to Dashboard


Which drugs does patent 11,058,668 protect, and when does it expire?

Patent 11,058,668 protects ATTRUBY and is included in one NDA.

This patent has twenty-four patent family members in sixteen countries.

Summary for Patent: 11,058,668
Title:Methods of treating TTR amyloidosis using AG10
Abstract:Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.
Inventor(s):Uma Sinha, Satish Rao
Assignee: Eidos Therapeutics Inc
Application Number:US16/361,587
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

United States Patent 11,058,668: Acoramidis Patent Scope, Claims, Expiration and Competitive Landscape

US 11,058,668 protects a specific oral dosing regimen for Compound 1, identified as acoramidis hydrochloride, formerly AG10, in transthyretin amyloidosis. The independent claim requires a total daily dose of approximately 1,600 mg administered twice daily. The dependent claims extend coverage to ATTR cardiomyopathy, ATTR polyneuropathy, disease subtypes, clinical outcomes and increased serum transthyretin levels.

The patent is a method-of-use patent, not a composition-of-matter patent. Its commercial importance is tied to Attruby, acoramidis tablets, approved by the U.S. Food and Drug Administration for adults with wild-type or hereditary ATTR cardiomyopathy to reduce cardiovascular death and cardiovascular-related hospitalization.[1]

What drug does US 11,058,668 protect?

Compound 1 is acoramidis hydrochloride, an oral transthyretin stabilizer developed by Eidos Therapeutics and commercialized by BridgeBio Pharma through its subsidiary, eidos Therapeutics, and later through Attruby commercial operations.

Acoramidis is designed to stabilize the transthyretin tetramer and reduce dissociation into monomers that can misfold and form amyloid deposits. The claimed dose is consistent with the approved Attruby regimen of 800 mg orally twice daily, equivalent to 1,600 mg per day.[1]

Item Detail
Active ingredient Acoramidis hydrochloride
Former development code AG10
Product Attruby
Dosage form Oral tablet
Claimed daily dose About 1,600 mg
Claimed frequency Twice daily
Primary disease Transthyretin amyloidosis
Approved U.S. indication Wild-type or hereditary ATTR cardiomyopathy
Patent type Method of treatment and dosing
Patent US 11,058,668 B2
Patent assignee associated with development Eidos Therapeutics, Inc.
FDA approval date for Attruby November 22, 2024

What are the independent claims in US 11,058,668?

Claim 1 is the controlling independent claim. It requires all of the following:

  1. A subject has transthyretin amyloidosis.
  2. The subject receives Compound 1 in hydrochloride salt form.
  3. The drug is administered orally.
  4. The total daily dose is about 1,600 mg.
  5. Administration occurs twice daily.

The claim does not require a particular mutation, disease stage, clinical endpoint or biomarker response. It is therefore broad as to the type of TTR amyloidosis, but narrow as to the active compound, salt form, route, dose and frequency.

A product administered at 800 mg twice daily would fall within the literal dosing language if the product contains the claimed Compound 1 hydrochloride form and the indication involves TTR amyloidosis. A different dose, once-daily schedule, non-oral route or materially different chemical form could avoid one or more express limitations, subject to infringement analysis under equivalents and the patent's prosecution history.

How do the dependent claims expand patent coverage?

Claims 2 through 14 create separate fallback positions. They do not replace claim 1. Each depends on the limitations of claim 1 and adds a disease subtype, outcome or pharmacodynamic result.

Claims Added subject matter Commercial relevance
2 Broad list of TTR amyloidosis diseases and conditions Expands disease coverage beyond the approved cardiomyopathy indication
3 ATTR cardiomyopathy Directly aligns with the Attruby label
4 ATTR polyneuropathy Covers a separate clinical use not currently matching the principal U.S. label
5 Improved six-minute walk performance in ATTR cardiomyopathy Clinical outcome limitation
6 Reduced cardiovascular-related hospitalizations Directly relevant to the approved outcome
7 Reduced mortality Directly relevant to the approved outcome
8 Improved Neuropathy Impairment Score in ATTR polyneuropathy Neurologic efficacy limitation
9 Wild-type ATTR cardiomyopathy Covers ATTRwt-CM
10 Familial or hereditary ATTR cardiomyopathy Covers ATTRm-CM
11 Wild-type ATTR polyneuropathy Covers ATTRwt-PN
12 Familial ATTR polyneuropathy Covers ATTRm-PN
13 Increased serum TTR concentration Pharmacodynamic limitation
14 At least 10% serum TTR increase after 28 days Quantified pharmacodynamic limitation

The commercial core is claims 1, 3, 5, 6, 7, 9 and 10. Claims 3, 9 and 10 track the approved ATTR cardiomyopathy population. Claims 5 through 7 correspond to functional and clinical outcomes evaluated in the ATTRibute-CM program and reflected in the product's regulatory positioning.[1][2]

What is the scope of the 1,600 mg twice-daily dosing claim?

The dosing limitation is central. "About 1,600 mg" generally provides some numerical flexibility around the stated dose, but the precise scope depends on the specification, prosecution history and claim construction. The claim is not limited to exactly 800 mg per tablet. It covers the total daily amount when administered twice daily.

Potentially covered regimens include:

  • 800 mg twice daily;
  • two 400 mg units twice daily;
  • another twice-daily presentation delivering approximately 1,600 mg per day;
  • treatment of either hereditary or wild-type ATTR cardiomyopathy; and
  • treatment of other TTR amyloidosis conditions listed in claim 2.

The claim does not expressly require the two doses to be exactly 12 hours apart. It also does not expressly require treatment for a minimum duration. The dependent serum TTR claim adds a 28-day treatment period, but that limitation does not apply to every claim.

A generic applicant could attempt to design around the patent by pursuing a different daily dose or dosing frequency. Such a strategy would face regulatory and clinical constraints because the approved product regimen is 800 mg twice daily, and a materially different regimen would require supporting bioequivalence, pharmacokinetic and labeling analysis.

What diseases are covered by the patent?

Claim 2 lists a wide range of TTR amyloidosis manifestations, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy, senile systemic amyloidosis, ocular amyloidosis, leptomeningeal amyloidosis, vitreous amyloidosis, gastrointestinal amyloidosis and cerebral amyloidosis.

Claims 3 and 4 separately identify:

  • ATTR cardiomyopathy; and
  • ATTR polyneuropathy.

Claims 9 through 12 divide these diseases by genetic status:

  • wild-type ATTR cardiomyopathy;
  • familial ATTR cardiomyopathy;
  • wild-type ATTR polyneuropathy; and
  • familial ATTR polyneuropathy.

The patent therefore reaches beyond Attruby's initial FDA-approved cardiomyopathy indication at the claim level. Patent coverage does not itself authorize a new indication. Commercial promotion and approved use remain governed by the FDA-approved labeling and applicable off-label-use rules.

What clinical outcomes are protected by US 11,058,668?

Claims 5 through 8 add measurable treatment outcomes.

For ATTR cardiomyopathy, the patent claims:

  • improved six-minute walk test performance;
  • decreased cardiovascular-related hospitalizations; and
  • decreased mortality.

For ATTR polyneuropathy, claim 8 covers improvement in the Neuropathy Impairment Score.

These claims create narrower infringement positions. A plaintiff would need to establish not only use of the claimed drug and dosing regimen, but also the relevant disease and outcome limitation. Claims 6 and 7 are commercially important because cardiovascular hospitalization and mortality reduction are central clinical endpoints for ATTR cardiomyopathy.

Claims 13 and 14 cover a pharmacodynamic response: increased serum TTR concentration, including at least a 10% increase from baseline after 28 days. Those claims may be useful in a dispute involving clinical protocols or induced infringement, although proving the required biomarker response in individual patients could create an evidentiary issue.

What is the FDA and Orange Book status of Attruby?

The FDA approved Attruby, acoramidis tablets, under NDA 217806 on November 22, 2024. The approved indication is reduction of cardiovascular death and cardiovascular-related hospitalization in adults with wild-type or hereditary ATTR cardiomyopathy.[1]

The product is a small-molecule drug, so biosimilar legislation does not apply. Future competitors would use the Abbreviated New Drug Application pathway rather than the biosimilar pathway.

Patent listing is significant because a listed method-of-use patent can trigger a certification requirement for an ANDA applicant. The applicant may submit:

  • Paragraph I, if no relevant patent information is listed;
  • Paragraph II, if the patent has expired;
  • Paragraph III, if the applicant will wait until patent expiration; or
  • Paragraph IV, if the applicant asserts that the patent is invalid, unenforceable or will not be infringed.

The commercial effect depends on whether US 11,058,668 is listed for the relevant NDA and use code in the current Orange Book. The supplied claim set establishes strong alignment with the approved Attruby indication, but it does not establish the current Orange Book listing record or use-code wording. An Orange Book listing should be verified against the FDA's current publication before relying on a Paragraph IV timetable.

When does US 11,058,668 lose exclusivity?

The patent's expected base term runs approximately 20 years from its earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and any applicable patent-term extension. Public patent records identify the patent as a continuation-family method patent associated with the acoramidis development program.[3]

A precise effective expiration date should be taken from the USPTO Patent Center record and the current Orange Book listing. The patent number alone does not establish whether patent-term adjustment has been added. The statutory patent term can also differ from the date shown in commercial patent databases.

Separate regulatory exclusivity applies:

Exclusivity Expected period
New chemical entity exclusivity Five years from November 22, 2024, subject to applicable statutory rules
Orphan-drug exclusivity Seven years for the approved orphan indication, generally through November 22, 2031
Patent exclusivity Dependent on the patent family, term adjustment and any listed related patents
Pediatric exclusivity No conclusion from the supplied record

Orphan exclusivity does not necessarily block an ANDA for every use of acoramidis. It protects the approved orphan indication and can coexist with a patent challenge directed to other claims or indications. A generic applicant may also pursue a skinny-label strategy if it can carve out protected use language and avoid marketing the patented indication.

How strong is the patent estate for acoramidis?

US 11,058,668 is important but should not be treated as the entire acoramidis estate. It is a regimen and method patent. The broader commercial estate may include separate patents directed to:

  • the acoramidis chemical entity;
  • hydrochloride salts;
  • solid forms and polymorphs;
  • pharmaceutical compositions;
  • tablets and excipients;
  • manufacturing processes;
  • treatment of ATTR cardiomyopathy;
  • treatment of ATTR polyneuropathy;
  • dosing regimens; and
  • biomarker or clinical-response methods.

The strength of US 11,058,668 is highest against an ANDA that proposes the same active ingredient, oral route, approximately 1,600 mg daily dose and twice-daily schedule for ATTR cardiomyopathy. Its strength is lower against:

  • a materially different dosing schedule;
  • a different salt or solid form;
  • a non-ATTR indication;
  • a label that omits the claimed method of use; or
  • a product launched after relevant patent expiration.

The patent does not independently prevent manufacture of acoramidis. Manufacturing restrictions would generally require separate composition, process or formulation claims.

Which companies are challenging the acoramidis patent?

Acoramidis has no biosimilar challenge pathway because it is a small molecule. The relevant competitors are generic pharmaceutical companies that may file ANDAs after the applicable filing date and regulatory exclusivity barriers.

A Paragraph IV challenge would likely target one or more of the following propositions:

  1. The claims are invalid for lack of novelty or obviousness.
  2. "About 1,600 mg" is indefinite or lacks adequate written-description support.
  3. The clinical outcome limitations are not adequately supported.
  4. The accused product does not use the claimed hydrochloride form.
  5. The proposed label does not induce infringement.
  6. The patent is unenforceable because of prosecution or inequitable-conduct issues.

No named Paragraph IV challenger, federal patent litigation docket or settlement agreement is established by the claim text supplied. Public litigation and Orange Book records should be reviewed before assigning a litigation probability or launch date.

What generic launch scenarios exist for Attruby?

The principal scenarios are:

Scenario Commercial effect
No Paragraph IV filing Generic entry generally waits for patent and regulatory barriers to expire
Paragraph IV filing with notice May trigger a 30-month stay if statutory conditions are met
Successful invalidity or noninfringement challenge Earlier launch becomes possible
Skinny-label approval Generic may launch for unpatented indications, subject to label and inducement risks
At-risk launch Generic enters before final resolution and faces damages or injunction exposure
Settlement Entry date depends on agreement terms and antitrust scrutiny
Patent expiry with orphan exclusivity remaining Indication-specific generic restrictions may continue

Attruby's commercial protection is concentrated in ATTR cardiomyopathy. A generic could face substantial exposure if its labeling reproduces the approved 800 mg twice-daily regimen and the cardiomyopathy indication.

What revenue exposure does the patent create?

The patent protects the commercially approved dosing regimen rather than a narrow investigational use. That makes it more relevant to near-term revenue protection than a patent limited to an unapproved endpoint.

Revenue exposure depends on:

  • Attruby net sales growth;
  • the number of patients receiving 800 mg twice daily;
  • the timing of ANDA filings;
  • the scope of any Orange Book use code;
  • the presence of separate composition or formulation patents;
  • orphan exclusivity through approximately 2031; and
  • the outcome of any Paragraph IV litigation.

A successful generic launch against the cardiomyopathy indication could affect substantially all U.S. product revenue because the approved label centers on that population. A narrow carve-out for polyneuropathy would have limited immediate commercial effect because polyneuropathy is not the principal approved U.S. indication.

How does acoramidis compare with tafamidis?

Acoramidis and tafamidis are both transthyretin stabilizers, but their patent and regulatory positions differ.

Attribute Acoramidis Tafamidis
Brand Attruby Vyndaqel, Vyndamax
Sponsor BridgeBio/Eidos Pfizer
Mechanism TTR tetramer stabilization TTR tetramer stabilization
Approved CM use Wild-type and hereditary ATTR-CM Wild-type and hereditary ATTR-CM
Approved dosing 800 mg twice daily Product-specific dosing; Vyndamax is 80 mg once daily
Product type Small molecule Small molecule
Biosimilar pathway Not applicable Not applicable
Key patent issue Dose, method and broader acoramidis estate Multiple composition, formulation and method patents
Clinical competition ATTR-CM ATTR-CM and established market position

Acoramidis's twice-daily 1,600 mg regimen is a defining limitation of US 11,058,668. Tafamidis does not practice that acoramidis-specific claim because it contains a different active ingredient.

Key Takeaways

  • US 11,058,668 is a method-of-treatment patent for oral acoramidis hydrochloride.
  • Claim 1 requires approximately 1,600 mg per day administered twice daily.
  • Claims 3, 9 and 10 directly cover ATTR cardiomyopathy, including wild-type and hereditary disease.
  • Claims 5 through 7 cover improved functional performance, reduced cardiovascular hospitalizations and reduced mortality.
  • Claims 13 and 14 cover increased serum TTR, including a 10% increase after 28 days.
  • The patent is commercially relevant to Attruby because its core regimen matches the FDA-approved 800 mg twice-daily dose.
  • Acoramidis is a small molecule; biosimilar litigation is not applicable.
  • Generic competition would proceed through the ANDA and Paragraph IV framework.
  • Exact patent expiration, Orange Book listing, use code, litigation status and settlement terms require confirmation from current USPTO, FDA and court records.
  • The patent is one component of the broader acoramidis estate, which may include composition, salt, formulation, solid-form and manufacturing patents.

FAQs About US 11,058,668 and Acoramidis Patent Protection

Is US 11,058,668 a composition-of-matter patent?

No. The supplied claims are method-of-treatment claims. They protect administering acoramidis hydrochloride at approximately 1,600 mg per day in two doses.

Does the patent cover acoramidis once-daily dosing?

Claim 1 expressly requires twice-daily administration. A once-daily regimen would not literally satisfy that limitation, although infringement analysis would depend on the full patent record and doctrine-of-equivalents issues.

Does US 11,058,668 cover ATTR polyneuropathy?

Yes. Claim 4 covers ATTR polyneuropathy, while claims 11 and 12 specify wild-type and familial forms. The patent's polyneuropathy claims do not establish FDA approval for that indication.

Can a generic launch with a label excluding ATTR cardiomyopathy?

Potentially, if the carve-out is legally and regulatorily effective. The generic applicant would need to avoid promoting or labeling the patented cardiomyopathy use and assess induced-infringement exposure.

Is acoramidis protected by orphan-drug exclusivity?

Attruby received FDA approval for an orphan disease indication, and orphan-drug exclusivity generally lasts seven years from approval for the protected indication. The precise scope depends on the FDA orphan designation and exclusivity record.

References

  1. U.S. Food and Drug Administration. (2024, November 22). Attruby (acoramidis) prescribing information. FDA.

  2. BridgeBio Pharma, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.

  3. U.S. Patent and Trademark Office. (2021). U.S. Patent No. 11,058,668, Methods of treating transthyretin amyloidosis. USPTO.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,058,668

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bridgebio Pharma ATTRUBY acoramidis hydrochloride TABLET;ORAL 216540-001 Nov 22, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,058,668

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2019239291 ⤷  Start Trial
Australia 2025206411 ⤷  Start Trial
Canada 3094711 ⤷  Start Trial
China 112218632 ⤷  Start Trial
Eurasian Patent Organization 202092272 ⤷  Start Trial
European Patent Office 3768841 ⤷  Start Trial
Israel 277379 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.